Albumin: An Emerging Opportunity in Drug Delivery

被引:26
作者
Rahimizadeh, Parastou [1 ]
Yang, Sungtae [2 ]
Lim, Sung In [1 ]
机构
[1] Pukyong Natl Univ, Dept Chem Engn, Busan 48513, South Korea
[2] Chosun Univ, Dept Microbiol, Sch Med, Gwangju 61452, South Korea
基金
新加坡国家研究基金会;
关键词
human serum albumin; drug delivery; drug carrier; conjugation; nanoparticle; fusion; HUMAN SERUM-ALBUMIN; HALF-LIFE; THERAPEUTIC PROTEIN; FUSION PROTEIN; NANOPARTICLES; DESIGN; PACLITAXEL; CONJUGATE; DOXORUBICIN; FORMULATION;
D O I
10.1007/s12257-019-0512-9
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
Albumin, the most abundant and long-lived serum protein, exhibits novel features as a carrier that can greatly enhance the pharmacological action of therapeutic payloads. Besides passive trafficking by enhanced permeability and retention effect, albumin has been shown to accumulate within the tumor environment or inflamed tissues by receptor-mediated active transport, lending itself to being a promising scaffold for targeted drug delivery. Albumin has recently been found to be a scavenger for amyloid-beta with the potential to treat neurodegenerative diseases. The hydrophobic binding pockets, conjugatable thiol residue, and surface-exposed N- and C-termini in albumin inherently serve as useful spots for carrying various kinds of peptidyl and non-peptidyl drugs. Beyond its long-standing role as a half-life extender, albumin is emerging as a versatile drug carrier to aid numerous therapeutic agents that have poor pharmacokinetics, targetability, solubility, and instabilityin vivo.
引用
收藏
页码:985 / 995
页数:11
相关论文
共 79 条
  • [1] Strategies for the production of long-acting therapeutics and efficient drug delivery for cancer treatment
    AlQahtani, Alanod D.
    O'Connor, David
    Domling, Alexander
    Goda, Sayed K.
    [J]. BIOMEDICINE & PHARMACOTHERAPY, 2019, 113
  • [2] Extending Serum Half-life of Albumin by Engineering Neonatal Fc Receptor ( FcRn) Binding
    Andersen, Jan Terje
    Dalhus, Bjorn
    Viuff, Dorthe
    Ravn, Birgitte Thue
    Gunnarsen, Kristin Stoen
    Plumridge, Andrew
    Bunting, Karen
    Antunes, Filipa
    Williamson, Rebecca
    Athwal, Steven
    Allan, Elizabeth
    Evans, Leslie
    Bjoras, Magnar
    Kjaerulff, Soren
    Sleep, Darrell
    Sandlie, Inger
    Cameron, Jason
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 2014, 289 (19) : 13492 - 13502
  • [3] Cross-species Binding Analyses of Mouse and Human Neonatal Fc Receptor Show Dramatic Differences in Immunoglobulin G and Albumin Binding
    Andersen, Jan Terje
    Daba, Muluneh Bekele
    Berntzen, Goril
    Michaelsen, Terje E.
    Sandlie, Inger
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 2010, 285 (07) : 4826 - 4836
  • [4] Bairagi U., 2015, AUSTIN THER, V2, P1021
  • [5] Design and characterization of MP0250, a tri-specific anti-HGF/anti-VEGF DARPin® drug candidate
    Binz, H. Kaspar
    Bakker, Talitha R.
    Phillips, Douglas J.
    Cornelius, Andreas
    Zitt, Christof
    Gottler, Thomas
    Sigrist, Gabriel
    Fiedler, Ulrike
    Ekawardhani, Savira
    Dolado, Ignacio
    Saliba, Johan Abram
    Tresch, Gaby
    Proba, Karl
    Stumpp, Michael T.
    [J]. MABS, 2017, 9 (08) : 1262 - 1269
  • [6] Plasma exchange for Alzheimer's disease Management by Albumin Replacement (AMBAR) trial: Study design and progress
    Boada, Merce
    Lopez, Oscar
    Nunez, Laura
    Szczepiorkowski, Zbigniew M.
    Torres, Mireia
    Grifols, Carlota
    Paez, Antonio
    [J]. ALZHEIMERS & DEMENTIA-TRANSLATIONAL RESEARCH & CLINICAL INTERVENTIONS, 2019, 5 (01) : 61 - 69
  • [7] Mini-review: Targeted radiopharmaceuticals incorporating reversible, low molecular weight albumin binders
    Brandt, Marie
    Cardinale, Jens
    Giammei, Carolina
    Guarrochena, Xabier
    Happl, Barbara
    Jouini, Nedra
    Mindt, Thomas L.
    [J]. NUCLEAR MEDICINE AND BIOLOGY, 2019, 70 : 46 - 52
  • [8] Human Serum Albumin-TRAIL Conjugate for the Treatment of Rheumatoid Arthritis
    Byeon, Hyeong Jun
    Min, Sun Young
    Kim, Insoo
    Lee, Eun Seong
    Oh, Kyung Taek
    Shin, Beom Soo
    Lee, Kang Choon
    Youn, Yu Seok
    [J]. BIOCONJUGATE CHEMISTRY, 2014, 25 (12) : 2212 - 2221
  • [9] Caspersen MB, 2017, THER DELIV, V8, P511, DOI 10.4155/tde-2017-0038
  • [10] Chemical Conjugation of Evans Blue Derivative: A Strategy to Develop Long-Acting Therapeutics through Albumin Binding
    Chen, Haojun
    Wang, Guohao
    Lang, Lixin
    Jacobson, Orit
    Kiesewetter, Dale O.
    Liu, Yi
    Ma, Ying
    Zhang, Xianzhong
    Wu, Hua
    Zhu, Lei
    Niu, Gang
    Chen, Xiaoyuan
    [J]. THERANOSTICS, 2016, 6 (02): : 243 - 253